Inventor · disambiguated record
Miha Kosmac
Also filed as: KOSMAC MIHA
18 granted patents·13 pending applications·347 citations·filing 2015–2025
95Inventor score
Files withKYMAB LTD31
Top patents by PatentIndex Score
31 records- 0198US9234043B1Anti-human OX40L antibodiesKYMAB LTD·Filed 2015·Granted Jan 12, 2016·21 cites·20 claims
- 0298US9139653B1Anti-human OX40L antibodies and methods of treatmentKYMAB LTD·Filed 2015·Granted Sep 22, 2015·38 cites·27 claims
- 0397US9617338B1Antibodies and immunocytokinesKYMAB LTD·Filed 2016·Granted Apr 11, 2017·78 cites·20 claims
- 0497US9567399B1Antibodies and immunocytokinesKYMAB LTD·Filed 2016·Granted Feb 14, 2017·96 cites·21 claims
- 0597US9512229B2Synergistic combinations of OX40L antibodies for the treatment of GVHDKYMAB LTD·Filed 2016·Granted Dec 6, 2016·12 cites·30 claims
- 0696US10604576B2Antibodies and immunocytokinesKYMAB LTD·Filed 2017·Granted Mar 31, 2020·25 cites·14 claims
- 0796US9957323B2Anti-ICOS antibodiesKYMAB LTD·Filed 2017·Granted May 1, 2018·27 cites·26 claims
- 0896US9868790B2Synergistic combinations of OX40L antibodies for the treatment of GvHDKYMAB LTD·Filed 2017·Granted Jan 16, 2018·11 cites·29 claims
- 0996US9868789B2Synergistic combinations of OX40L antibodies for the treatment of GvHDKYMAB LTD·Filed 2017·Granted Jan 16, 2018·11 cites·19 claims
- 1094US11396550B2Methods of treating comprising administering anti-OX40L antibodiesKYMAB LTD·Filed 2017·Granted Jul 26, 2022·4 cites·54 claims
- 1193US9434785B1Anti-human OX40L antibodies and methods of treating graft versus host disease with the sameKYMAB LTD·Filed 2015·Granted Sep 6, 2016·16 cites·30 claims
- 1291US11773175B2Antibodies, uses and methodsKYMAB LTD·Filed 2021·Granted Oct 3, 2023·1 cites·19 claims
- 1388US12209128B2Anti-PD-L1 antibodiesKYMAB LTD·Filed 2021·Granted Jan 28, 2025·1 cites·6 claims
- 1488US11965026B2Anti-PD-L1 and IL-2 cytokinesKYMAB LTD·Filed 2017·Granted Apr 23, 2024·3 cites·19 claims
- 1588US2024132605A1Antibodies, uses & methodsKYMAB LTD·Filed 2023·Application pending·0 cites
- 1685US11858996B2Anti-ICOS antibodiesKYMAB LTD·Filed 2017·Granted Jan 2, 2024·2 cites·29 claims
- 1783US2024360218A1Anti-pd-l1 and il-2 cytokinesKYMAB LTD·Filed 2024·Application pending·0 cites
- 1883US2024343810A1Multispecific antibodies for immuno-oncologyKYMAB LTD·Filed 2024·Application pending·0 cites
- 1981US2024158502A1Anti-icos antibodiesKYMAB LTD·Filed 2023·Application pending·0 cites
- 2079US2025263492A1Antibodies, uses & methodsKYMAB LTD·Filed 2025·Application pending·0 cites
- 2178US11753479B2Nucleic acids encoding anti-OX40L antibodiesKYMAB LTD·Filed 2020·Granted Sep 12, 2023·0 cites·21 claims
- 2277US2022380467A1Anti-icos antibodiesKYMAB LTD·Filed 2022·Application pending·0 cites
- 2377US2022403029A1Anti-icos antibodiesKYMAB LTD·Filed 2022·Application pending·0 cites
- 2477US2023312720A1Multispecific antibodies for immuno-oncologyKYMAB LTD·Filed 2022·Application pending·0 cites
- 2575US11440960B2TIGIT antibodies, encoding nucleic acids and methods of using said antibodies in vivoKYMAB LTD·Filed 2018·Granted Sep 13, 2022·1 cites·14 claims
- 2670US2023192847A1Tigit antibodies, encoding nucleic acids and methods of using said antibodies in vivoKYMAB LTD·Filed 2022·Application pending·0 cites
- 2769US2019276547A1Antibodies, uses & methodsKYMAB LTD·Filed 2018·Application pending·0 cites
- 2861US2022372153A1Synergistic combinations of ox40l antibodies for the treatment of gvhdKYMAB LTD·Filed 2022·Application pending·0 cites
- 2960US2017037137A1Synergistic combinations of ox40l antibodies for the treatment of gvhdKYMAB LTD·Filed 2016·Application pending·0 cites
- 3056US2020190191A1Multispecific antibody with combination therapy for immuno-oncologyKYMAB LTD·Filed 2017·Application pending·0 cites
- 3153US12435134B2Antagonists anti-CD7 antibodiesKYMAB LTD·Filed 2020·Granted Oct 7, 2025·0 cites·22 claims
Join the waitlist — get patent alerts
Get an alert when Miha Kosmac files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →